Clinical Trials Logo

Advanced Metastatic Melanoma clinical trials

View clinical trials related to Advanced Metastatic Melanoma.

Filter by:
  • None
  • Page 1

NCT ID: NCT04152863 Terminated - Clinical trials for Advanced/Metastatic Melanoma

Efficacy, Safety, and Tolerability of Gebasaxturev (V937) Administered Intravenously or Intratumorally With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone in Participants With Advanced/Metastatic Melanoma (V937-011)

Start date: June 5, 2020
Phase: Phase 2
Study type: Interventional

This is a Phase 2 study to assess the efficacy, safety, and tolerability of gebasaxturev administered both intratumorally (ITu) and intravenously (IV) as combination therapy with pembrolizumab (MK-3475) versus pembrolizumab alone in anti-programmed cell death ligand 1 (anti-PD-L1)-treatment-naive participants with advanced/metastatic melanoma. The primary hypothesis of the study is that gebasaxturev administered either ITu or IV in combination with pembrolizumab results in a superior objective response rate (ORR) per Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST 1.1) based on blinded independent central review (BICR), compared to pembrolizumab alone. This study will be terminated once all participants finish treatment with V937. Participants eligible to continue to receive pembrolizumab will be transferred to MK-3475-587 study.

NCT ID: NCT03957551 Recruiting - Clinical trials for Advanced Metastatic Melanoma

Cabozantinib and Pembrolizumab for Advanced Metastatic Melanoma

Start date: August 27, 2019
Phase: Phase 1/Phase 2
Study type: Interventional

The study aims to evaluate the safety and preliminary efficacy of the combination of cabozantinib and pembrolizumab in advanced melanoma

NCT ID: NCT00948467 Completed - Clinical trials for Advanced Non-hematologic Malignancies

Study of TAK-733 in Adult Patients With Advanced Nonhematologic Malignancies

Start date: December 2009
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety, pharmacokinetics, pharmacodynamics and maximum tolerated dose of TAK-733 in patients with advanced, nonhematologic tumors. The expansion stage of the study will evaluate evidence of antitumor activity of TAK-733 in patients with advanced metastatic melanoma.